

TÜV Rheinland LGA Products GmbH • 51105 Köln

NAWA Heilmittel GmbH
Ostendstraße 100
90482, Nürnberg
Germany

Contact

Tel. +49 911 655-5225
Mail: medical-products@de.tuv.com

Date February 15, 2024

Notified Body Confirmation Letter

Reference.: NAWA_PLA1_607_2024-02-02, order #1156630

To whom it may concern,

Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation EU 2023/607 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices.

This letter confirms that **TÜV Rheinland LGA Products GmbH**, a Notified Body (NB) designated against Regulation (EU) 2017/745 (MDR) and identified by the number **0197** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of MDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of MDR with the following manufacturer:

NAWA Heilmittel GmbH
Ostendstraße 100
90482, Nürnberg
Germany
SRN Number: DE-MF-000009460

The devices covered by the formal application and the written agreement mentioned above are identified in the tables below. Table 1 identifies the devices for which an MDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance under the applicable Directive. Table 2 identifies the devices for which an MDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive.

In the case of devices covered by certificates issued under Directive 90/385/EEC (AIMDD) or Directive 93/42/EEC (MDD) that expired after May 26, 2021 but before March 20, 2023 without having been withdrawn, this letter also confirms that the manufacturer either signed the written agreement under MDR by the date of MDD/AIMDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 59(1) of MDR or Article 97(1) of the MDR respectively, by March 20, 2023 for the relevant devices.

TÜV Rheinland
LGA Products GmbH

Am Grauen Stein
51105 Köln
Germany

Headquarter

Tillystraße 2
90431 Nuremberg

Phone. +49 911 655 5225
Fax +49 911 655 5226
service@de.tuv.com
www.tuv.com/safety

Board of Management

Dipl.-Ing.
Thomas Weigand, Spokesman

Dipl.-Kfm.
Dr. Jörg Schlösser

Nuremberg HRB 26013
VAT No.: DE 811835490

Chairman of the
Supervisory Board

Dr.-Ing. Michael Fübi

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 120.3c of MDR (as amended by (EU) 2023/607), are shown below:

- May 26, 2026 for Class III custom-made implantable devices
- December 31, 2027 for Class III devices and Class IIb implantable devices excluding Well-established technologies (WET - sutures, staples, dental fillings, dental braces, tooth crowns, screws, wedges, plates, wires, pins, clips and connectors)
- December 31, 2028 for other Class IIb devices, Class IIa, Class I devices placed on the market in sterile condition or have a measuring function
- December 31, 2028 for devices not requiring the involvement of a notified body under MDD but requiring it under MDR (e.g., class I devices that qualify as re-usable surgical instruments)

On behalf of the Notified Body

Digital
unterschrieben
Dr. K. Kluge von Karsten Kluge
Datum: 2024.02.15
i.V. Dr. K. Kluge 19:22:00 +01'00'
Certification body

Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Elektrolyt-Salbe S	IIa	N/A	Certificate #HD 60133236 0001 NB #0197
First Aid Spray/ Wundspray	IIa	N/A	Certificate #HD 60133236 0001 NB #0197
Herpesgel	IIa	N/A	Certificate #HD 60133236 0001 NB #0197
Wundspray plus/ Wundreinigungsspray	IIa	N/A	Certificate #HD 60133236 0001 NB #0197
ZIS-Gel plus	IIa	N/A	Certificate #HD 60133236 0001 NB #0197

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
Lipogel	IIb non-implantable	N/A	Certificate #HD 60133236 0001 NB #0197
NAWAlution	IIb non-implantable	N/A	Certificate #HD 60133236 0001 NB #0197
NAWAlution Gel	IIb non-implantable	N/A	Certificate #HD 60133236 0001 NB #0197
Hydrogel	IIb non-implantable	N/A	Certificate #HD 60133236 0001 NB #0197

Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:

Device name or Basic UDI-DI (under MDR application)	MDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the MDR device is a substitute device, identification of the corresponding MDD/AIMDD device	MDD/AIMDD Certificate Reference(s) of the devices under MDR application, and the NB Identification
N/A	N/A	N/A	N/A

Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2024/02/15	NAWA_CL607_2024-02-15	Initial issue
YYYY/MM/DD	XXXXXXXXXX	Addition of device XYZ to the list
YYYY/MM/DD	XXXXXXXXXX	Removal of device XYZ to the list